PKO Investment Management Joint Stock Co Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

PKO Investment Management Joint Stock Co raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 41.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,300 shares of the biopharmaceutical company's stock after acquiring an additional 4,500 shares during the period. Regeneron Pharmaceuticals makes up about 1.1% of PKO Investment Management Joint Stock Co's portfolio, making the stock its 21st biggest holding. PKO Investment Management Joint Stock Co's holdings in Regeneron Pharmaceuticals were worth $9,704,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $25,000. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the last quarter. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Finally, Curat Global LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $4.72 on Wednesday, reaching $513.58. 841,026 shares of the company's stock traded hands, compared to its average volume of 884,759. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The stock's 50 day simple moving average is $561.15 and its two-hundred day simple moving average is $645.97. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The stock has a market cap of $55.45 billion, a PE ratio of 13.07, a PEG ratio of 1.86 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the business earned $9.55 earnings per share. The business's quarterly revenue was down 3.7% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $700.00 to $580.00 in a research report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.